Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results of the PAGE-B cohort

Study limitation reported by the research below: “The cohort is exclusively Caucasian (PAGE-B cohort); results may not apply to Asian or African CHB populations, who carry the majority of the global disease burden and have different baseline HCC risk profiles.”